HLA-C*06:02 Negativity Shouldn ' t Bar Ustekinumab Treatment for Psoriasis HLA-C*06:02 Negativity Shouldn ' t Bar Ustekinumab Treatment for Psoriasis

Although being positive for the HLA-C*06:02 genotype is associated with a better response to ustekinumab therapy in patients with plaque psoriasis, those with negative findings also do well, according to Dutch researchers.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Dermatology News Source Type: news